Last reviewed 2026-04-22 · How we verify

Hep-V Vax

University of Oxford · FDA-approved active Biologic

Hep-V Vax is a Viral vector vaccine Biologic drug developed by University of Oxford. It is currently FDA-approved for Hepatitis C virus infection (prophylactic or therapeutic).

Hep-V Vax is a viral vector-based vaccine that delivers hepatitis C viral antigens to stimulate immune responses against hepatitis C infection.

Hep-V Vax is a viral vector-based vaccine that delivers hepatitis C viral antigens to stimulate immune responses against hepatitis C infection. Used for Hepatitis C virus infection (prophylactic or therapeutic).

At a glance

Generic name	Hep-V Vax
Sponsor	University of Oxford
Drug class	Viral vector vaccine
Target	Hepatitis C virus antigens
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

The vaccine uses a modified viral vector platform to present hepatitis C virus (HCV) antigens to the immune system, triggering both cellular and humoral immune responses. This approach aims to generate protective immunity against HCV infection or to enhance immune control in chronically infected individuals. The vaccine is designed to elicit T-cell and antibody responses targeting conserved HCV epitopes.

Approved indications

Hepatitis C virus infection (prophylactic or therapeutic)

Common side effects

Injection site reactions
Fever
Fatigue
Myalgia

Key clinical trials

Qidong Hepatitis B Intervention Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hep-V Vax CI brief — competitive landscape report
Hep-V Vax updates RSS · CI watch RSS
University of Oxford portfolio CI

Frequently asked questions about Hep-V Vax

What is Hep-V Vax?

Hep-V Vax is a Viral vector vaccine drug developed by University of Oxford, indicated for Hepatitis C virus infection (prophylactic or therapeutic).

How does Hep-V Vax work?

Hep-V Vax is a viral vector-based vaccine that delivers hepatitis C viral antigens to stimulate immune responses against hepatitis C infection.

What is Hep-V Vax used for?

Hep-V Vax is indicated for Hepatitis C virus infection (prophylactic or therapeutic).

Who makes Hep-V Vax?

Hep-V Vax is developed and marketed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).

What drug class is Hep-V Vax in?

Hep-V Vax belongs to the Viral vector vaccine class. See all Viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is Hep-V Vax in?

Hep-V Vax is FDA-approved (marketed).

What are the side effects of Hep-V Vax?

Common side effects of Hep-V Vax include Injection site reactions, Fever, Fatigue, Myalgia.

What does Hep-V Vax target?

Hep-V Vax targets Hepatitis C virus antigens and is a Viral vector vaccine.

Drug class: All Viral vector vaccine drugs
Target: All drugs targeting Hepatitis C virus antigens
Manufacturer: University of Oxford — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Hepatitis C virus infection (prophylactic or therapeutic)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing